prompt,answer
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-01-08 to 2023-01-15, AMGN's stock price decreased from 265.98 to 262.63. Company news during this period are listed below:

[Headline]: IBB: A History Of Outperformance During Recessions
[Summary]: iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now.

[Headline]: FOCUS-Drug companies favor biotech meds over pills, citing new U.S. law
[Summary]: Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives biologics a longer runway before becoming subject to government price limits, top industry executives said this week.  The Inflation Reduction Act (IRA), which Democrats passed last August, for the first time allows the government's Medicare health plan for people age 65 and over to negotiate the prices it is willing to pay for certain medications.  The pharmaceutical industry, whose members gathered in the thousands this week in San Francisco for the annual JP Morgan Healthcare conference, opposed the legislation and has begun implementing strategies to mitigate its impact.

[Headline]: Amgen (AMGN) Gains But Lags Market: What You Should Know
[Summary]: Amgen (AMGN) closed at $271.73 in the latest trading session, marking a +0.3% move from the prior day.

[Headline]: Amgen: Dividend Growth Secure But Keep An Eye On Debt, Margins
[Summary]: Amgen has been able to grow dividends at a rate of 11% over the past 5 years. Read more to know why AMGN stock is a hold at its current valuation.

[Headline]: 25 Biggest California Companies and Stocks
[Summary]: In this article, we will be taking a look at the 25 biggest California companies and stocks. To skip our detailed analysis, you can go directly to see the 5 Biggest California Companies and Stocks. California is not just the most populous state in the U.S. with over 39 million residents, but it is also […]

Some recent basic financials of AMGN, reported at 2022-12-31, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.4257
bookValue: 3661
cashRatio: 0.48632625741059476
currentRatio: 1.4143
ebitPerShare: 4.145
eps: 3.0037
ev: 171455
fcfMargin: 0.3376
fcfPerShareTTM: 16.4513
grossMargin: 0.7446
inventoryTurnoverTTM: 1.421
longtermDebtTotalAsset: 0.5736
longtermDebtTotalCapital: 0.8767
longtermDebtTotalEquity: 10.2032
netDebtToTotalCapital: 0.735
netDebtToTotalEquity: 8.5539
netMargin: 0.2363
operatingMargin: 0.3261
payoutRatioTTM: 0.6404
pb: 38.2789
peTTM: 21.3887
pfcfTTM: 15.9521
pretaxMargin: 0.2556
psTTM: 5.3238
quickRatio: 1.1
receivablesTurnoverTTM: 5.034
roaTTM: 0.106
roeTTM: 2.4611
roicTTM: 0.1621
rotcTTM: 0.2386
salesPerShare: 12.7119
sgaToSale: 0.2554
totalDebtToEquity: 10.6378
totalDebtToTotalAsset: 0.598
totalDebtToTotalCapital: 0.9141
totalRatio: 1.0596

Based on all the information before 2023-01-15, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-01-15 to 2023-01-22) is down by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Industry Tailwinds: The biotech sector has a history of outperformance during recessions. This indicates potential resilience for Amgen during economic downturns.
2. Changing Landscape: With recent legislation changes in the US promoting complex biotech medicines over pills for their longer price protection, there is a potential increase in demand for Amgen's portfolio.
3. Dividend Growth: Amgen's continued dividend growth at a rate of 11% over the past 5 years may appeal to income-focused investors.

[Potential Concerns]:
1. High Debt Ratio: Amgen has a high debt-to-equity ratio (10.6378), indicating a significant use of debt to finance its activities. This could be a potential risk if the company isn't generating enough cash to meet its debt obligations.
2. Margins and Debt: Investors should keep an eye on Amgen's rising debt and shrinking margins, which could hamper its profitability in the long run.
3. Medication Price Reduction: The new Inflation Reduction Act could lead to potential price reductions for certain medications, which might affect the company's revenue and profit.

[Prediction & Analysis]:

Even with the positive developments including potential industry resilience during a recession and increased legislative interest in biotech medicines, there are serious concerns over Amgen's financial health. High debt levels and potential negative impact from legislation on pricing may pose substantial risks to the company's profitability and, by extension, its stock price. Considering all these factors, my prediction is that Amgen's stock price will likely trend down by approximately 3-4% in the upcoming week.
"
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-01-08 to 2023-01-15, AMGN's stock price decreased from 265.98 to 262.63. Company news during this period are listed below:

[Headline]: Amgen Inc. stock outperforms competitors despite losses on the day
[Summary]: Shares of Amgen Inc. slid 1.85% to $270.12 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
[Summary]: Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors
[Summary]: Shares of Amgen Inc. slipped 0.35% to $272.91 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: FDRR: Designed For Inflation And Still Unconvincing
[Summary]: Fidelity Dividend ETF for Rising Rates ETF invests in dividend stocks that should profit from rising rates. Here's a rundown on FDRR and whether it is right for you.

[Headline]: 2023 Market Preview: Value Should Continue To Lead
[Summary]: The market's history after negative years is usually positive. What we expect to work in 2023: Industrials and consumer staples. Click for our market preview.

From 2023-01-15 to 2023-01-22, AMGN's stock price decreased from 262.63 to 254.42. Company news during this period are listed below:

[Headline]: 25 Biggest California Companies and Stocks
[Summary]: In this article, we will be taking a look at the 25 biggest California companies and stocks. To skip our detailed analysis, you can go directly to see the 5 Biggest California Companies and Stocks. California is not just the most populous state in the U.S. with over 39 million residents, but it is also […]

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. slid 1.87% to $264.39 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock falls Thursday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 0.89% to $262.03 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen (AMGN) Presents At 41st Annual Healthcare Conference - Slideshow
[Summary]: The following slide deck was published by Amgen Inc.

[Headline]: 3 Dividend Stocks You Can Safely Hold for Years
[Summary]: Most companies currently paying dividends are equipped to do so for the foreseeable future.  Only a handful of dividend-paying companies, however, are built to continue dishing out dividends into the distant unknown as unforeseen changes arise.  Here's a closer look at three dividend stocks you can safely hold for years.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-01-22, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-01-22 to 2023-01-29) is down by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen has a history of beating earnings estimates, which may indicate a strong financial performance in its upcoming report. 
2. Amgen continues to outperform competitors during unfavorable trading sessions, showing resilience and potential for recovery. 

[Potential Concerns]:
1. Amgen has had a consistent slip in stock price for the past two weeks, which suggests a bearish trend. 
2. It underperformed in comparison to the market on multiple days, which speaks to potential investor concern or decreasing confidence in the company.

[Prediction & Analysis]:

Despite showing resilience and consistently outclassing its peers in difficult trading sessions, the continued slide in Amgen's stock price cannot be ignored. The company has underperformed in comparison to the market in recent weeks, which signifies a potential lack of investor confidence in the current company's future. With no new basic financial information to counter the view created by these stock market performances and no significant recent news to buoy the stock, next week is likely to follow the same bearish trend. 

Additionally, while maintaining a good track record in beating earnings estimates is reassuring, it doesn't assure that this trend will continue, and even a slight miss could exacerbate fears and accelerate the decline. For the upcoming week (2023-01-22 to 2023-01-29), we predict that the company's stock will likely decrease by 3-4% considering the existing circumstances."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-01-15 to 2023-01-22, AMGN's stock price decreased from 262.63 to 254.42. Company news during this period are listed below:

[Headline]: Amgen Reinforcing Its Portfolio
[Summary]: Amgen's newly acquired products bring in almost $1 billion quarterly, all from the U.S. Read what this could mean for AMGN stock in the coming years.

[Headline]: Amgen Inc. stock falls Thursday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 0.89% to $262.03 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen (AMGN) Presents At 41st Annual Healthcare Conference - Slideshow
[Summary]: The following slide deck was published by Amgen Inc.

[Headline]: Insiders who sold Amgen Inc.'s (NASDAQ:AMGN) earlier this year didn't have to weather this week's 3.1% slide
[Summary]: Amgen Inc.'s (NASDAQ:AMGN) value has fallen 3.1% in the last week, but insiders who sold US$5.2m worth of stock over...

[Headline]: 3 Dividend Stocks You Can Safely Hold for Years
[Summary]: Most companies currently paying dividends are equipped to do so for the foreseeable future.  Only a handful of dividend-paying companies, however, are built to continue dishing out dividends into the distant unknown as unforeseen changes arise.  Here's a closer look at three dividend stocks you can safely hold for years.

From 2023-01-22 to 2023-01-29, AMGN's stock price decreased from 254.42 to 245.15. Company news during this period are listed below:

[Headline]: 2 Top Passive-Income Stocks to Own in 2023
[Summary]: Passive-income stocks are a proven way to cushion your portfolio against market volatility.  What's more, top shelf dividend plays also tend to outperform other asset classes in bull markets.  Not all dividend stocks are cut from the same cloth, however.

[Headline]: Why Viridian Therapeutics Is One Of My 2023 Top Picks
[Summary]: Viridian was one of my top picks in 2022 and it made the 2023 list again. Click here to see our take on VRDN stock.

[Headline]: Warren tells FTC she is ""particularly concerned"" about Amgen and Indivior deals
[Summary]: Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.  In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.  ""Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market,"" she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats.

[Headline]: UPDATE 2-U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals
[Summary]: Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.  In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.  ""Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market,"" she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats.

[Headline]: Bristol Myers Gets CHMP Backing for Sotyktu, Reblozyl >BMY
[Summary]: By Colin Kellaher Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-01-29, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-01-29 to 2023-02-05) is down by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's newly acquired products are bringing in nearly $1 billion quarterly, suggesting a strengthening income stream.
2. The company continues to be identified as a solid player in dividend stock selection, offering consistent and reliable returns for investors.

[Potential Concerns]:
1. The steady decrease of AMGN's stock performance over the last two weeks suggests a weakening investor sentiment. 
2. Insider selling of AMGN stock points to potential internal concerns about the company's prospects.
3. Senator Elizabeth Warren's letter to the FTC expressing concern about Amgen's potential acquisitions could indicate regulatory hurdles and reputational risks ahead for the company. 

[Prediction & Analysis]:

Given the recent negative news and AMGN's decreasing stock performance over the last two weeks, it seems likely that the stock price could continue to drop next week. The internal concerns displayed via insider selling could further dampen investor confidence. Also, the potential regulatory and political headwinds expressed in Senator Warren's letter could create uncertainty about Amgen's upcoming acquisitions, which might result in further hesitance among investors. Therefore, I predict a continued downward trend for AMGN's stock in the week of 2023-01-29 to 2023-02-05, with a potential decrease of around 3-4%."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-01-29 to 2023-02-05, AMGN's stock price decreased from 245.15 to 236.96. Company news during this period are listed below:

[Headline]: Amgen Inc. (AMGN) Q4 2022 Earnings Call Transcript
[Summary]: Call Start: 16:30 January 1, 0000 6:00 PM ETAmgen Inc.

[Headline]: Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
[Summary]: While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors
[Summary]: Shares of Amgen Inc. slipped 2.37% to $246.41 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...

[Headline]: US STOCKS-Wall St falls as Fed decision looms; AMD boosts chipmakers
[Summary]: U.S. stock indexes fell on Wednesday ahead of the Federal Reserve's decision on interest rates later in the day, while an upbeat outlook from Advanced Micro Devices lifted chipmakers.  The Fed is widely seen as raising its target interest rate by a quarter of a percentage point in its first policy meeting of the year, after rapid increases in 2022 to tame decades-high inflation.

[Headline]: Why Amgen Stock Wilted on Wednesday
[Summary]: The stock of veteran biotech Amgen (NASDAQ: AMGN) was looking a little tired on Wednesday.  The company's shares fell more than 2% in price, ""thanks"" to fourth-quarter results that didn't put smiles on investors' faces.  In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-02-05, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-02-05 to 2023-02-12) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. released their Q4 2022 Earnings Call Transcript, providing investors and stakeholders with further transparency.
2. Comparison against estimates and year-ago values illuminates the performance of the company and can aid in decision-making processes.

[Potential Concerns]:
1. Amgen underperformed on Wednesday, compared to other competitors, indicating potential competition concerns or internal business issues.
2. The Federal Reserve's decision on interest rates impacted Wall Street stocks and might increase inflation risks in 2023, which could negatively impact the company's profitability.
3. The company's latest Q4 results didn't meet investors' expectations, which subsequently led to a decline in the share price, signaling a potential lack of confidence in the company’s profitability.

[Prediction & Analysis]:

The stock price movements of Amgen Inc. has shown a downward trend recently with less-than-expected Q4 results, dragging down investors' optimism and causing the stock price to dip. Furthermore, the increased competition in the market and potential increase in interest rates pose an imminent risk to the profitability and stability of the company.

While the comprehensive disclosure in the Q4 Earnings Call is a positive step towards transparency, it will not be enough to offset the impact of the financial underperformance and concerns about the Federal Reserve's decisions. 

Therefore, given the current uncertainties and the recent downturn in company stock price, it is predicted that the stock price of Amgen may continue to decline by roughly 1-2% for the upcoming week from 2023-02-05 to 2023-02-12."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-02-05 to 2023-02-12, AMGN's stock price decreased from 236.96 to 234.38. Company news during this period are listed below:

[Headline]: AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?
[Summary]: The day has arrived: Biosimilars for AbbVie's blockbuster drug Humira are now being sold in the US. See whether it's not time to sell ABBV?

[Headline]: Amgen Inc. stock outperforms market despite losses on the day
[Summary]: Shares of Amgen Inc. shed 0.54% to $243.85 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock rises Tuesday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.06% higher to $244.00 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...

[Headline]: 9 Upcoming Dividend Increases
[Summary]: I've tracked 35 dividend increases in 2023 for your consideration. There are nine increases for next week, up from two last week. Click here to read more.

[Headline]: 12 Most Undervalued Dow Stocks To Buy According To Hedge Funds
[Summary]: In this article, we will take a look at the 12 most undervalued dow stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Dow Stocks To Buy According To Hedge Funds. The stock market bloodbath that started in 2022 has forced investors to shun the so-called […]

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-02-12, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-02-12 to 2023-02-19) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Despite losses, Amgen Inc. stocks have outperformed the market, indicating that investors retain confidence in the company.
2. The mention of Amgen Inc. as one of the most undervalued Dow stocks according to hedge funds implies that there's potential for growth and increased investment.
3. There are upcoming dividend increases, which can make shares of the company more attractive to certain investors.

[Potential Concerns]:
1. Biosimilars for AbbVie's blockbuster drug Humira are now being sold in the US. This could potentially pose a threat to Amgen's market share and pharmaceutical sales.
2. The general stock market whipsaw just seen can create an environment of uncertainty and instability for all stocks, including Amgen.

[Prediction & Analysis]:

Despite the potential threat posed by Humira's Biosimilars, Amgen seems to be holding its own in the market. Rising against a generally tough market and being listed as one of the most undervalued Dow stocks indicates a potentially strong position for the company. The anticipated dividend increases also increase the appeal of AMGN's stock to income-minded investors.

However, a cautious approach to the overall market condition is needed. In a turbulent market, even strong stocks can experience downward pressure. 

While predicting precise stock price movements is impossible, and although the aforementioned concerns are present, I predict that Amgen's stock is reasonably likely to experience an upward movement of around 0-1% for the week of February 12-19, 2023. This prediction is based on the relative strength of Amgen's performance despite market challenges, the potential pull factor from the anticipated dividend increases, and the implication of undervaluation which could drive increased purchase of the stock."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-02-05 to 2023-02-12, AMGN's stock price decreased from 236.96 to 234.38. Company news during this period are listed below:

[Headline]: AbbVie: The Dreaded Humira Cliff Is Here: Time To Sell?
[Summary]: The day has arrived: Biosimilars for AbbVie's blockbuster drug Humira are now being sold in the US. See whether it's not time to sell ABBV?

[Headline]: AbbVie’s stock gains on Q4 results
[Summary]: Shares of AbbVie Inc. gained 2.4% in premarket trading on Thursday after the company beat earnings expectations for the fourth quarter of 2022. AbbVie had a...

[Headline]: AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE
[Summary]: Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023. Susan Sweeney, senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

[Headline]: How This Income Method Could Lead To Financial Freedom
[Summary]: We will go over our thesis as to how a diversified income method with low volatility could make you financially independent. Click here for our strategy.

[Headline]: Dividend Champion, Contender, And Challenger Highlights: Week Of February 12
[Summary]: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Click here to read the update for the week of February 12.

From 2023-02-12 to 2023-02-19, AMGN's stock price increased from 234.38 to 234.52. Company news during this period are listed below:

[Headline]: 12 Most Undervalued Dow Stocks To Buy According To Hedge Funds
[Summary]: In this article, we will take a look at the 12 most undervalued dow stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Dow Stocks To Buy According To Hedge Funds. The stock market bloodbath that started in 2022 has forced investors to shun the so-called […]

[Headline]: Top Research Reports for Chevron, Novo Nordisk & Amgen
[Summary]: Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).

[Headline]: 5 Stocks In The Dividend Growth Sweet Spot
[Summary]: Finding companies with a high initial yield and rapid dividend growth is difficult. Here's my criteria for finding such companies.

[Headline]: Amgen Inc. stock outperforms competitors despite losses on the day
[Summary]: Shares of Amgen Inc. shed 0.40% to $240.07 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen to raise $24 billion after seeing about $90 billion in demand for mega bond deal
[Summary]: Amgen looks to raise $24 billion on Wednesday, ranking in the top 10 in terms of largest U.S. corporate bond deals ever, according to Informa Global Markets.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-02-19, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-02-19 to 2023-02-26) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen is set to present at the 2023 SVB Securities Global Biopharma Conference, increasing its visibility among analysts, investors, and industry professionals.
2. Amgen is undertaking a mega bond deal, aiming to raise $24 billion, which indicates the company's solid reputation and ability to attract high levels of interest from investors.
3. Market analysis reports ranked Amgen as one of the most undervalued stocks to buy according to hedge funds.

[Potential Concerns]:
1. The introduction of biosimilars for Abbvie's blockbuster drug Humira can pose a significant threat and create competition in the pharmaceutical market.
2. Though Amgen's stock outperformed some competitors, it still experienced losses on the day, indicating potential uncertainty or volatility in the market.

[Prediction & Analysis]:
Though Amgen displays strong industry participation and garnered positive financial attention, the upcoming week may see a minor decline in its stock price. The pricing dip could be attributed to the potential upheaval caused by the introduction of biosimilars for Humira, a direct competitor. Additionally, the overall market turbulence characterized by the company's recent losses, despite outperforming some competitors, lends to a cautious stance toward short-term stock performance. Thus, a downturn of 2-3% could be anticipated for the week of February 19 to February 26, 2023. However, Amgen's positive developments suggest a sound long-term investment perspective."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-02-12 to 2023-02-19, AMGN's stock price increased from 234.38 to 234.52. Company news during this period are listed below:

[Headline]: Amgen's (NASDAQ:AMGN) investors will be pleased with their notable 52% return over the last five years
[Summary]: While Amgen Inc. ( NASDAQ:AMGN ) shareholders are probably generally happy, the stock hasn't had particularly good run...

[Headline]: Amgen Inc. stock rises Monday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.48% higher to $243.66 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...

[Headline]: The Zacks Analyst Blog Highlights Chevron, Novo Nordisk, Amgen, Starbucks and General Dynamics
[Summary]: Chevron, Novo Nordisk, Amgen, Starbucks and General Dynamics are part of the Zacks top Analyst Blog.

[Headline]: Dow, Amgen share losses lead Dow's 225-point fall
[Summary]: Behind declines for shares of Dow and Amgen, the Dow Jones Industrial Average is trading down Thursday morning. Shares of Dow and Amgen have contributed to...

[Headline]: Dow closes more than 100 points higher on Friday, but notches third straight week of losses on rate fears: Live updates
[Summary]: A week of inflation and retail sales data has put the consumer in sharp focus. Recent comments from Fed officials have also spooked investors.

From 2023-02-19 to 2023-02-26, AMGN's stock price decreased from 234.52 to 227.82. Company news during this period are listed below:

[Headline]: Amgen: Re-Rating Seems Fair
[Summary]: Amgen has seen a near 15% pullback since the Horizon acquisition was announced in December. See why I am still a bit cautious on AMGN stock.

[Headline]: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock
[Summary]: In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...

[Headline]: Bristol Myers: Looking Good For 2023
[Summary]: Bristol Myers has seen a recent pullback in its share price, just like many other big pharma names. Check out why I'm bullish on BMY stock.

[Headline]: 12 Most Profitable Pharmaceutical Stocks Now
[Summary]: In this piece, we will take a look at 12 most profitable pharmaceutical stocks now. For more stocks, head on over to 5 Most Profitable Pharmaceutical Stocks Now. The pharmaceutical industry was the center of attention in 2020 and 2021 after the deadly coronavirus pandemic ravaged the globe and disrupted the way of living. As […]

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. slipped 1.67% to $233.66 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-02-26, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-02-26 to 2023-03-05) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. shareholders saw a pleasing return of 52% over the last five years, indicating sustained growth and profitability for the company.
2. It is part of Zacks' top analyst blog, highlighting its potential for growth and attractiveness to investors.
3. It consistently created positive trading sessions, notably with a 0.48% increase on a day when the S&P reported a generally positive performance.

[Potential Concerns]:
1. Substantial stock of the company, equating to a value of US$5.2m, was sold by insiders, signalling a potential lack of confidence in the company's future performance.
2. Amgen's share price has experienced a significant decrease of nearly 15% since the announcement of the Horizon acquisition.
3. The company underperformed in the market during a notably rough trading session, slipping by 1.67%.

[Prediction & Analysis]:

The stock price of Amgen Inc (NASDAQ:AMGN) is predicted to experience a minor increase of 0-1% in the upcoming week. The past performance has been notable with pleasant returns for investors. Moreover, its mention in Zacks’ top analyst blog suggests the company adequately meets the solid growth progression criteria, fuelling an optimistic outlook. 

However, caution is still advised due to various warning signs. Insider trading of the company's shares presents a significant concern. Furthermore, a significant pullback since the Horizon acquisition raises questions about the company's prospects. Finally, an underperforming day at the market hints at potential instability for the stock.

Conversely, it's worth noting that the global stock market has been fluctuating due to external factors like inflation and interest rate fears, affecting most stocks, including AMGN. Overall, Balancing the potential concerns with recent positive developments, the stock's movement prediction leans towards a slight increase."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-02-19 to 2023-02-26, AMGN's stock price decreased from 234.52 to 227.82. Company news during this period are listed below:

[Headline]: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock
[Summary]: In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...

[Headline]: Bristol Myers: Looking Good For 2023
[Summary]: Bristol Myers has seen a recent pullback in its share price, just like many other big pharma names. Check out why I'm bullish on BMY stock.

[Headline]: Amgen Inc. stock falls Tuesday, still outperforms market
[Summary]: Shares of Amgen Inc. slipped 0.95% to $238.24 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS
[Summary]: Amgen (NASDAQ:AMGN) today announced the African American Heart Study, in collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), which will measure the association between Lipoprotein(a), or Lp(a), and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States. ASCVD is defined as the buildup of cholesterol plaque in arteries and includes events such as heart attack and stroke.

[Headline]: Regeneron: Innovation And Disruption Done Right
[Summary]: Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now.

From 2023-02-26 to 2023-03-05, AMGN's stock price increased from 227.82 to 228.95. Company news during this period are listed below:

[Headline]: Tracking John Paulson's Paulson & Company Portfolio - Q4 2022 Update
[Summary]: John Paulsonâs 13F portfolio value decreased from $1.37B to $1.11B this quarter. Read more about Paulson & Company's holdings and trades for Q4 2022.

[Headline]: My $394k Portfolio Outperforms The Market Again In A Dreary February
[Summary]: My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Click to read more.

[Headline]: Amgen Inc. stock underperforms Thursday when compared to competitors
[Summary]: Shares of Amgen Inc. slumped 0.61% to $234.74 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: Amgen (AMGN) closed the most recent trading day at $234.74, moving -0.61% from the previous trading session.

[Headline]: March's 17 Ideal 2023 Barrons/Bloomberg Dividend Dogs
[Summary]: Ten top 2023 Bar/BI-projected dividend yields ranged from 4.78% to 7.94%. Click here for a detailed analysis.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-03-05, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-03-05 to 2023-03-12) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. The company has taken a proactive approach toward researching the association between Lipoprotein(a) and atherosclerotic cardiovascular disease in African Americans, aligning with industry trends toward personalized medicine.
2. The company's stock has outperformed the market during an overall downtrend in the stock market, indicating strong investor confidence.

[Potential Concerns]:
1. Insider selling of AMGN shares potentially indicates that insiders believe the company's stock price may decrease in the future.
2. The stock underperformed in a relative basis compared to its competitors, indicating a potential market shift towards its competitors.

[Prediction & Analysis]:

Although Amgen continues to innovate within the Biotechnology sector through research projects, the insider selling of company stock acts as a potent signal that the stock may not be poised for growth in the near future. Furthermore, its relative underperformance compared to its competitors suggest that it is not winning over the market despite the greater bearish sentiment. Given these developments, I predict that AMGN stock will see a decrease of about 2-3% in the upcoming week. The company's efforts in researching cardiovascular disease in African Americans indicates its strategic focus on personalized medicine, however, these endeavors are long-term and may not immediately affect stock prices. Thus, considering the immediate factors influencing market sentiment, the prognosis is a downward price movement for the next week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-03-05 to 2023-03-12, AMGN's stock price decreased from 228.95 to 222.18. Company news during this period are listed below:

[Headline]: Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet
[Summary]: David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

[Headline]: Amgen Inc. (AMGN) Presents at 43rd Annual TD Cowen Healthcare Conference (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) 43rd Annual TD Cowen Healthcare Conference March 8, 2023 11:10 AM ETCompany ParticipantsPeter Griffith - Executive Vice President and Chief Financial...

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: Amgen (AMGN) closed the most recent trading day at $228.43, moving -0.13% from the previous trading session.

[Headline]: New Drugs for Cancer, Rare Disease Can Now Cost More Than $20,000 a Month
[Summary]: As drugmakers face pressure to rein in price hikes on existing drugs, new medicines arrive with ever-higher prices on day one, contributing to rising costs for patients and stretched budgets for insurers.

[Headline]: Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year
[Summary]: Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-03-12, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-03-12 to 2023-03-19) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Healthy Financial Position: Amgen's robust balance sheet gives it the resilience to weather economic turmoil.
2. Strong Investor Confidence: Amgen's decision to increase its dividend payout from the previous year signals market confidence and could attract more investors.
3. Innovation and Market Presence: Amgen's consistent presence at industry conferences like the 43rd Annual TD Cowen Healthcare Conference demonstrates the company's market relevance and innovation capabilities.

[Potential Concerns]:
1. Market Pricing Volatility: Despite a strong financial outlook, Amgen's stock has been behaving inversely to market gains, and this could signify underlying industry or company-specific concerns.
2. High Drug Pricing: The rising cost of new drugs, a trend that Amgen appears to be a part of, has been a point of concern. This can lead to potential regulatory scrutiny, negatively affecting stock performance.
 
[Prediction & Analysis]:

Given the positive developments, Amgen's healthy balance sheet points to its capability to make strategic decisions and absorb shocks that could affect its financial performance. The increase of dividend payout is another positive sign, reinforcing the firm's flexibility and profitability. Meanwhile, despite recent mild stock price fluctuations, the company's proactive presence at industry discussions as reaffirmed at the 43rd Annual TD Cowen Healthcare Conference underscores its progressive character in the biotech space.

However, the current high pricing of new medicines points to possible future cost-related friction with consumers and regulatory bodies. Despite concerns, these are slightly mitigated by the company's healthy financial position and investor-friendly practices.

Considering these factors, there is an expectation of a minimal upward adjustment in stock price in the range of 0-1% for the upcoming week. The numerous positive aspects elaborated above indicate a more favorable near-term performance for the company, despite ever-present market uncertainties. It is this robust foundation, coupled with the company’s keen biotechnological vision, that makes a compelling case for its potential positive albeit slight performance."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-03-05 to 2023-03-12, AMGN's stock price decreased from 228.95 to 222.18. Company news during this period are listed below:

[Headline]: Spectrum's Rolvedon: An Undifferentiated, Small Player In A Vast Market
[Summary]: Spectrum Pharmaceuticals develops and commercializes cancer therapies, including Rolvedon. Read more to see why SPPI stock is a Sell.

[Headline]: 2 March Dogs Of The Dow To Buy, 4 More To Watch
[Summary]: The highest-yield 10 are Marchâs Dogs of the Dow: JNJ, KO, CSCO, AMGN, CVX, DOW, IBM, WBA, MMM, and VZ, averaging a 4.41% annual yield.

[Headline]: New Drugs Are Coming to Market at Sky-High Prices
[Summary]: A new  Amgen  lung-cancer treatment, Lumakras, carried a hefty price tag when it came out in 2021: $17,900 per patient monthly.  Just over a year later, in December 2022, a second drug for the same type of cancer, Krazati from  Mirati Therapeutics  had an even higher price: $19,750 a month—a 10% premium.  As drugmakers face rising pressure to rein in repeat or annual price hikes on existing drugs, new brand-name medicines are coming to market with ever-higher price tags on day one.

[Headline]: Assuming No-Growth, Gilead Is The Safest Choice Among The Large Biotechs
[Summary]: Gilead has a strong credit profile and a low cost of equity. Find out why for an investor seeking relative safety, GILD stock is worth a look.

[Headline]: The Near-Perfect Portfolio: Sleep Well During Turbulent Times
[Summary]: With the economy going through the boom and bust cycles more frequently, the extreme ups and downs of the market are inevitable. Read more here.

From 2023-03-12 to 2023-03-19, AMGN's stock price increased from 222.18 to 224.05. Company news during this period are listed below:

[Headline]: Microsoft, Amgen share gains lead the way, but Dow flat
[Summary]: The Dow Jones Industrial Average is flat Monday afternoon with shares of Microsoft and Amgen seeing positive growth for the price-weighted average. The Dow...

[Headline]: Amgen is sued for concealing $10.7 billion tax bill from investors
[Summary]: Amgen Inc has been sued in a proposed class action accusing the drugmaker of waiting too long to tell investors it might owe the Internal Revenue Service $10.7 billion in taxes and penalties.

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: Amgen (AMGN) closed at $230.58 in the latest trading session, marking a -1.12% move from the prior day.

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.87% to $234.90 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...

[Headline]: Amgen Inc. stock underperforms Friday when compared to competitors
[Summary]: Shares of Amgen Inc. slipped 2.04% to $229.79 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-03-19, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-03-19 to 2023-03-26) is up by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Spectrum Pharmaceuticals presents a weak competition: With its Lung cancer treatment Rolvedon considered a minor player in the market, competitors like Spectrum might not pose a strong threat to Amgen.
2. High potential returns: Amgen is listed as one of the 'Dogs of the Dow,' meaning that the company is seen as underpriced with a potential for high dividends.
3. New Products: Introduction of new products such as Lumakras, despite its extremely high-price tag, showcases Amgen's ability to innovate and generate revenue through new streams.

[Potential Concerns]:
1. Sky-high prices for new treatments: The heavy price tag on Amgen's lung cancer treatment Lumakras could potentially limit their customer base and subject the company to scrutiny and criticism.
2. Legal Trouble: The legal proceedings from the proposed class action lawsuit accusing Amgen of withholding information about a large tax bill pose a risk to company reputation and financial stability.

[Prediction & Analysis]:

Despite a few setbacks like the class-action lawsuit and criticism of high price tags on new treatments, the outlook for Amgen seems positive. The fact that the company has been listed as one of the 'Dogs of the Dow' indicates this perception among investors, suggesting a potential undervaluation of the company's shares and an opportunity for increased dividends. 

Additionally, the lack of severe competition in Amgen's primary sector allows AMGN to command a large share of the market. The successful introduction of a new product, Lumakras, demonstrates the company's capability to innovate, expand its product line and create new revenue streams. 

While the company faces potential criticisms and regulatory scrutiny due to high prices for their products, this points to substantial profit margins for these treatments, bolstering their revenue. Despite its legal issues, the company's fundamental business does not seem to be affected as such, and continuous innovation and market dominance in a niche sector make it poised for growth. 

With these developments, we expect Amgen's stock price to rise by about 3-4% in the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-03-12 to 2023-03-19, AMGN's stock price increased from 222.18 to 224.05. Company news during this period are listed below:

[Headline]: Amgen Inc. (AMGN) Oppenheimer 33rd Annual Healthcare Conference (Transcript)
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 2:00 PM ETCompany ParticipantsArvind Sood - Vice President, Investor RelationsSusan Sweeney -...

[Headline]: 2 Top Biotech Stocks to Buy Right Now
[Summary]: A high dividend yield and powerful growth prospects are a rare combination for any single stock to offer.  On one hand, a high yield often comes with the trade-off of an elevated dividend payout ratio and lower resulting growth potential.  On the other hand, a company with adequate growth opportunities will generally have a lower payout ratio to retain the capital needed for growth.

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. advanced 1.87% to $234.90 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...

[Headline]: Buy And Hold Coffee Can Portfolio For The Next 15 Years
[Summary]: This article covers topics from Christopher Mayer's book 

[Headline]: Amgen to cut about 450 jobs in second round of layoffs this year
[Summary]: Amgen Inc. on Thursday said it would lay off about 450 employees, or less than 2% of its workforce, as it faces increasing pressure from drug prices and high inflation.

From 2023-03-19 to 2023-03-26, AMGN's stock price increased from 224.05 to 232.09. Company news during this period are listed below:

[Headline]: Mirati's Krazati: A Strong Competitor In The KRAS G12C-Mutated NSCLC Market
[Summary]: Mirati Therapeutics's Krazati could capture a significant share of the 2L KRAS G12C-mutated NSCLC market. Click here to read why MRTX stock is a Buy.

[Headline]: 3 Dow Stocks Near 52-Week Lows That Look Like Bargains Now
[Summary]: The past 15 months have been disastrous for the major stock market indexes, but one has fared better than its peers.  The Dow Jones Industrial Average has fallen around 12% since the end of 2021.  While traditionally filled with industrial and financial stocks, there aren't any specific rules that determine which companies become one of the Dow's 30 components.

[Headline]: Horizon Therapeutics: Attractive 7.16% Upside To Amgen Deal
[Summary]: Horizon Therapeutics Public Limited Company is a $25 billion biotech Amgen Inc. is acquiring. Click here to read our view of the HZNP-AMGN deal.

[Headline]: Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
[Summary]: In the latest trading session, Amgen (AMGN) closed at $232.95, marking a -0.75% move from the previous day.

[Headline]: Amgen Inc. stock outperforms market on strong trading day
[Summary]: Shares of Amgen Inc. rose 2.11% to $238.03 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...

Some recent basic financials of AMGN, reported at 2023-03-31, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3784
bookValue: 5348
cashRatio: 2.2201899402040097
currentRatio: 3.1448
ebitPerShare: 3.7807
eps: 5.2807
ev: 159129.5
fcfMargin: 0.1179
fcfPerShareTTM: 14.103
grossMargin: 0.7245
inventoryTurnoverTTM: 1.3855
longtermDebtTotalAsset: 0.6849
longtermDebtTotalCapital: 0.9077
longtermDebtTotalEquity: 11.3614
netDebtToTotalCapital: 0.4487
netDebtToTotalEquity: 5.6161
netMargin: 0.4654
operatingMargin: 0.3332
payoutRatioTTM: 0.5372
pb: 24.1388
peTTM: 16.306
pfcfTTM: 17.1417
pretaxMargin: 0.5638
psTTM: 4.9292
quickRatio: 2.7923
receivablesTurnoverTTM: 4.8442
roaTTM: 0.1144
roeTTM: 2.0999
roicTTM: 0.1659
rotcTTM: 0.1924
salesPerShare: 11.3476
sgaToSale: 0.2755
totalDebtToEquity: 11.5174
totalDebtToTotalAsset: 0.6943
totalDebtToTotalCapital: 0.9201
totalRatio: 1.0641

Based on all the information before 2023-03-26, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-03-26 to 2023-04-02) is up by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. During its participation in the Oppenheimer 33rd Annual Healthcare Conference, AMGN likely had the opportunity to impress shareholders and prospective investors, potentially raising its outlook.
2. The company's shares have outperformed competitors in strong trading days, indicating an active and robust market presence.
3. Acquisition of Horizon Therapeutics has been a strategically positive move, potentially extending its product offerings.

[Potential Concerns]:
1. The company recently announced to cut about 450 jobs, which could possibly affect daily operations and reduce morale among the remaining employees.
2. AMGN's stock showed slight instability, sinking even as the market gained. This indicates that its gains may not be entirely sustainable.
3. High long-term debts in comparison to total assets, equities, and capital which could strain the company's financial flexibility.

[Prediction & Analysis]:
Considering the recent developments, including the Horizon Therapeutics acquisition and the strong market performance, it can be inferred that the company is making strategic declarations for long-term growth. However, the job cuts signal potential internal issues and restructuring that investors will be watching closely.

Despite the potential concerns, Amgen displays a strong operational resilience, hinted at by its outperformance in the market during strong trading days, as well as its consistent revenue generation potential shown by a good roeTTM (return on equity on trailing twelve months) and roicTTM (return on invested capital). 

However, the concern over high long-term debt might moderate the price upswing, but considering the overall positive signs, it's predicted that the stock price for AMGN will likely rise by 1-2% over the next week (2023-03-26 to 2023-04-02)."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-03-26 to 2023-04-02, AMGN's stock price increased from 232.09 to 235.71. Company news during this period are listed below:

[Headline]: UPDATE 1-U.S. Supreme Court hears Amgen bid to revive cholesterol drug patents
[Summary]: The U.S. Supreme Court on Monday began hearing a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc.

[Headline]: U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents
[Summary]: U.S. Supreme Court justices on Monday weighed a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.

[Headline]: Amgen Inc. stock underperforms Monday when compared to competitors
[Summary]: Shares of Amgen Inc. shed 0.53% to $236.76 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. stock rises Wednesday, still underperforms market
[Summary]: Shares of Amgen Inc. rallied 1.07% to $241.03 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

[Headline]: This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips
[Summary]: T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment.

Some recent basic financials of AMGN, reported at 2023-03-31, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3784
bookValue: 5348
cashRatio: 2.2201899402040097
currentRatio: 3.1448
ebitPerShare: 3.7807
eps: 5.2807
ev: 159129.5
fcfMargin: 0.1179
fcfPerShareTTM: 14.103
grossMargin: 0.7245
inventoryTurnoverTTM: 1.3855
longtermDebtTotalAsset: 0.6849
longtermDebtTotalCapital: 0.9077
longtermDebtTotalEquity: 11.3614
netDebtToTotalCapital: 0.4487
netDebtToTotalEquity: 5.6161
netMargin: 0.4654
operatingMargin: 0.3332
payoutRatioTTM: 0.5372
pb: 24.1388
peTTM: 16.306
pfcfTTM: 17.1417
pretaxMargin: 0.5638
psTTM: 4.9292
quickRatio: 2.7923
receivablesTurnoverTTM: 4.8442
roaTTM: 0.1144
roeTTM: 2.0999
roicTTM: 0.1659
rotcTTM: 0.1924
salesPerShare: 11.3476
sgaToSale: 0.2755
totalDebtToEquity: 11.5174
totalDebtToTotalAsset: 0.6943
totalDebtToTotalCapital: 0.9201
totalRatio: 1.0641

Based on all the information before 2023-04-02, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-04-02 to 2023-04-09) is up by 4-5%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Supreme Court hearing: The US Supreme Court considered Amgen's bid to revive patents on its cholesterol drug, Repatha. If successful, it could curb competition and increase potential sales revenue.
2. Positive market trading: Despite underperforming compared to some competitors, the overall market trading session was favorable for Amgen Inc. 

[Potential Concerns]:
1. Legal risk: The outcome of the patent revival request is uncertain. Not winning could mean increased competition for their drug, potentially impacting revenues.
2. Financial risk: The high total debt to equity ratio of 11.5174 is worrying. Having too much debt compared to equity could pose significant risks if the company runs into financial trouble. 

[Prediction & Analysis]:

Though it underperformed slightly earlier in the week, the stock showed positive momentum towards the end, especially on Wednesday. This dynamic, combined with the Supreme Court hearing, leads me to predict a moderate increase in the stock price in the coming week.

The potential revival of patents on Repatha could lead to market exclusivity and increased profit from the drug, providing a positive signal to investors. However, the high debt level represents potential financial risk, which deserves attention.

In summary, given the positive trend in trading and the potential added value from the patent hearing, assuming no major negative macroeconomic news that can potentially impact the entire stock market, there is a good chance that AMGN's stock price might increase around 4-5% in the week of April 2 to April 9, 2023. Investors should continue to keep tabs on the legal proceedings and financial health of the company."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-04-02 to 2023-04-09, AMGN's stock price increased from 235.71 to 246.99. Company news during this period are listed below:

[Headline]: A March ~6% Gain In My 25 Stock $417k Portfolio Beats The Market For The Third Time In 2023
[Summary]: My portfolio, built specifically for my retirement ~20 years from now, features growth, dividends, and risk stocks for a happy retirement. Click here for a detailed analysis.

[Headline]: 3 Dow Stocks With Above-Average Dividends Yields to Buy in April
[Summary]: Income-seeking investors are going to love the annual payout raises and yields of 2.9% or better that these legendary dividend payers offer right now.

[Headline]: Dogs Of The Dow Stumble In First Quarter
[Summary]: The Dogs of the Dow strategy has the sole focus of investing in the highest dividend-yielding stocks in the Dow Jones Industrial Average Index.

[Headline]: Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
[Summary]: Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

[Headline]: Love Dividends? These 3 Stocks Are Smart Buys Right Now
[Summary]: Receiving cash payments every three months is one obvious attraction.  If you're looking for businesses that can make and raise dividend payments regardless of an uncooperative economic environment, it's hard to do better than the healthcare sector.  While you're most likely familiar with CVS Health's (NYSE: CVS) chain of retail pharmacies, most don't realize that retail is a small part of this company's overall business.

Some recent basic financials of AMGN, reported at 2023-03-31, are presented below:

[Basic Financials]:

assetTurnoverTTM: 0.3784
bookValue: 5348
cashRatio: 2.2201899402040097
currentRatio: 3.1448
ebitPerShare: 3.7807
eps: 5.2807
ev: 159129.5
fcfMargin: 0.1179
fcfPerShareTTM: 14.103
grossMargin: 0.7245
inventoryTurnoverTTM: 1.3855
longtermDebtTotalAsset: 0.6849
longtermDebtTotalCapital: 0.9077
longtermDebtTotalEquity: 11.3614
netDebtToTotalCapital: 0.4487
netDebtToTotalEquity: 5.6161
netMargin: 0.4654
operatingMargin: 0.3332
payoutRatioTTM: 0.5372
pb: 24.1388
peTTM: 16.306
pfcfTTM: 17.1417
pretaxMargin: 0.5638
psTTM: 4.9292
quickRatio: 2.7923
receivablesTurnoverTTM: 4.8442
roaTTM: 0.1144
roeTTM: 2.0999
roicTTM: 0.1659
rotcTTM: 0.1924
salesPerShare: 11.3476
sgaToSale: 0.2755
totalDebtToEquity: 11.5174
totalDebtToTotalAsset: 0.6943
totalDebtToTotalCapital: 0.9201
totalRatio: 1.0641

Based on all the information before 2023-04-09, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-04-09 to 2023-04-16) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:

1. AMGN has an impressive earnings surprise history, indicating strong financial performance, which could drive the stock price up.
2. The company operates in the healthcare sector, which is known for its sturdy and reliable nature, especially during tough economic times. 
3. AMGN has seen a strong performance in its stock portfolio, growing by approximately 6% in March.

[Potential Concerns]:
1. AMGN has a high long-term debt to total asset ratio of approximately 0.69, which may indicate a high level of financial risk and potential difficulties in the future.
2. AMGN is part of the ""Dogs of the Dow"" strategy, focusing on high-yielding dividend stocks. The strategy has struggled in the first quarter, suggesting possible underperformance.
3. The company's payout ratio is 0.5372, which may reveal that the company is not retaining sufficient earnings for future investment and growth.

[Prediction & Analysis]:


Given the company's recent strong financial performance, as indicated by its earnings surprise history, there is a likelihood that the stock price may rise in the short term. However, high levels of long-term debt pose a significant risk to the company's future financial health. This could deter some investors, potentially driving the stock price down. 

Additionally, the recent underperformance of stocks involved in the ""Dogs of the Dow"" strategy could further impact AMGN's stock price negatively, as investors could perceive this as a potential risk. Furthermore, AMGN's relatively high payout ratio might deter potential investors who are looking for companies that reinvest more profits back into the business.

Therefore, even though the company has shown positive developments in the recent weeks, there are some considerable potential risks. Including these factors, and assuming that the overall market does not have significant fluctuation, I would predict that AMGN's stock price could see a slight decline of around 1-2% in the upcoming week. This prediction is based mainly on concerns over AMGN's long-term debt levels, its involvement with the underperforming ""Dogs of the Dow"" strategy, and payout ratio."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-04-09 to 2023-04-16, AMGN's stock price decreased from 246.99 to 243.76. Company news during this period are listed below:

[Headline]: Amgen Inc. stock falls Monday, underperforms market
[Summary]: Shares of Amgen Inc. slumped 0.96% to $250.90 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: DivHut Portfolio Update: March 2023
[Summary]: The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book.

[Headline]: Amgen Inc. stock rises Thursday, still underperforms market
[Summary]: Shares of Amgen Inc. inched 0.78% higher to $251.44 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...

[Headline]: Amgen (AMGN) Gains But Lags Market: What You Should Know
[Summary]: Amgen (AMGN) closed the most recent trading day at $251.44, moving +0.78% from the previous trading session.

[Headline]: 7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows
[Summary]: Many investors have heard the phrase “cash is king” relative to the current banking crisis. But it also has significance for dividend investors. A company’s cash flow, and particularly its free cash flow, is an important indicator for investors trying to determine how safe a dividend payout is. This article highlights seven dividend stocks with strong cash flows. And I’ve put an emphasis on free cash flow. Free cash flow is simply the money a company has left (or free to use) after it has paid o

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-04-16, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-04-16 to 2023-04-23) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. There has been steady growth of the company's stock price across the week, underperforming the market but nevertheless showing a steady gain in value.
2. The company featured on the list of '7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows'. This suggests the company's dividends are backed by a healthy cash flow, which is a positive sign for potential investors.

[Potential Concerns]:
1. The headline ""Amgen (AMGN) Gains But Lags Market"" suggests that although the company is seeing some growth, it is not keeping pace with the overall market trend. This could be a concerning sign for potential investors.
2. The news ""Amgen Inc. stock falls Monday, underperforms market"" highlights that the company's stock performance during the start of the week was disappointing.

[Prediction & Analysis]:

My prediction for AMGN's stock price movement for the upcoming week is a decline by 2-3%. The company has shown an overall underperformance when compared to the market in the past week, indicating potentially less investor confidence or lackluster company performance in the Biotechnology sector. While there are some positive developments for the company, such as steady growth and recognition for strong cash flows supporting its dividends, the company's underperformance and inconsistent growth could hint at a downward trend in the upcoming week. Therefore, predicting a slight decline seems reasonable based on the recent financial news and market trends. This prediction will need to be re-evaluated if more recent news or financial reports come to light."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-04-09 to 2023-04-16, AMGN's stock price decreased from 246.99 to 243.76. Company news during this period are listed below:

[Headline]: Love Dividends? These 3 Stocks Are Smart Buys Right Now
[Summary]: Receiving cash payments every three months is one obvious attraction.  If you're looking for businesses that can make and raise dividend payments regardless of an uncooperative economic environment, it's hard to do better than the healthcare sector.  While you're most likely familiar with CVS Health's (NYSE: CVS) chain of retail pharmacies, most don't realize that retail is a small part of this company's overall business.

[Headline]: Why Healthcare Stocks Are A Prescription For Investors In Q2 2023
[Summary]: The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. shed 0.77% to $249.50 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own
[Summary]: Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

[Headline]: 7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows
[Summary]: Many investors have heard the phrase “cash is king” relative to the current banking crisis. But it also has significance for dividend investors. A company’s cash flow, and particularly its free cash flow, is an important indicator for investors trying to determine how safe a dividend payout is. This article highlights seven dividend stocks with strong cash flows. And I’ve put an emphasis on free cash flow. Free cash flow is simply the money a company has left (or free to use) after it has paid o

From 2023-04-16 to 2023-04-23, AMGN's stock price decreased from 243.76 to 237.77. Company news during this period are listed below:

[Headline]: 7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows
[Summary]: Many investors have heard the phrase “cash is king” relative to the current banking crisis. But it also has significance for dividend investors. A company’s cash flow, and particularly its free cash flow, is an important indicator for investors trying to determine how safe a dividend payout is. This article highlights seven dividend stocks with strong cash flows. And I’ve put an emphasis on free cash flow. Free cash flow is simply the money a company has left (or free to use) after it has paid o

[Headline]: Amgen Inc. stock underperforms Monday when compared to competitors
[Summary]: Shares of Amgen Inc. dropped 0.77% to $248.07 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...

[Headline]: UPDATE 1-US Amgen ruling keeps generic psoriasis drug off market until 2028
[Summary]: Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.  The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey federal court's ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.  The Federal Circuit also upheld a decision to invalidate one of Amgen's patents that Sandoz said would have barred its generics until 2034.

[Headline]: ClearBridge SMID Cap Growth Strategy Q1 2023 Portfolio Manager Commentary
[Summary]: 

[Headline]: Investing in Amgen (NASDAQ:AMGN) five years ago would have delivered you a 59% gain
[Summary]: If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-04-23, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-04-23 to 2023-04-30) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc has recently acquired Horizon Therapeutics, enabling the company to diversify its pharmaceutical portfolio and potentially increase future revenues.
2. An article highlighted the company as one of the seven dividend stocks with strong cash flows, signifying the firm's stable financial footing and its ability to provide reliable dividends.
3. The company managed to uphold its patents on its blockbuster psoriasis drug, Otezla, effectively barring competition until 2028, which could boost revenue and ensure market dominance in the sector.

[Potential Concerns]:
1. Over the past two weeks, Amgen's stock has been consistently underperforming, presenting a worrisome trend for investors.
2. The stock market experienced a grim trading session, which also negatively impacted Amgen's shares.
3. Generic versions of Amgen's popular drug, Otezla, are expected to enter the market in 2028, potentially diluting future revenue streams.

[Prediction & Analysis]:
Considering the positive developments and potential concerns, the prediction for next week (2023-04-23 to 2023-04-30) is a decrease by 1-2% in the stock price.

While Amgen exhibits strong financial footing and promising growth through the acquisition of Horizon Therapeutics and upholding of patent rights, the company has been consistently underperforming in the past weeks. This, coupled with the overall gloomy performance of the stock market, poses some level of concern for investors. While Amgen's long-range financial potential remains robust, these short-term worries and market dynamics appropriately support a minor forecasted decrease in the stock price for the upcoming week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-04-23 to 2023-04-30, AMGN's stock price decreased from 237.77 to 233.75. Company news during this period are listed below:

[Headline]: Oppenheimer Maintains AMGEN (AMGN) Outperform Recommendation
[Summary]: 

[Headline]: Amgen 1Q Net Income Surges Despite 2% Dip in Revenue
[Summary]: By Denny Jacob Amgen Inc. net income surged in the latest quarter even as revenue declined slightly. The biotechnology company logged net income of $2.84...

[Headline]: UPDATE 1-Amgen 1st quarter profit falls as costs rise, sales flatten
[Summary]: Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.  Product sales by volume grew 14% from a year earlier, but net selling prices fell 5%, while foreign exchange rates and other factors also limited sales revenue gains, Amgen said.  Amgen is seeing prescription trends return to prepandemic levels and ""demand for medicines is resilient despite current macroeconomic challenges,"" Amgen Chief Executive Robert Bradway said on a conference call with investors.

[Headline]: Amgen 1st quarter profit falls as costs rise, sales up 2%
[Summary]: Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.

[Headline]: Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised
[Summary]: Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-04-30, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-04-30 to 2023-05-07) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. The company has exceeded market expectations for earnings and has also raised its earnings and sales guidance for 2023. These positive signs can lead to increased investor confidence.
2. Its first quarter net income surged despite a slight dip in revenue. This suggests effective management of operational expenses, hence profitability.
3. Product sales by volume grew 14% from a year earlier, indicating increased demand for the company's products.

[Potential Concerns]:
1. The company has experienced lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co. Considering the role of COVID-19 treatments in boosting revenues for biotechnology companies in recent times, this could negatively impact the company's financial performance.
2. Oppenheimer's outperform recommendation, albeit positive, can create heightened expectations among investors that, if not met, can lead to a sell-off.
3. Rising costs are diminishing profits, and could indicate potential operational inefficiencies.

[Prediction & Analysis]:

Despite some positive developments, the company's revenue dip and the decline in earnings from its COVID-19 antibody manufacturing deal create potential headwinds for the stock. The disappointing revenue performance may lead investors to reassess the stock’s valuation, especially considering the increased expenses. Therefore, a slight downward price movement of 1-2% seems probable for the upcoming week.

Moreover, the fact that net selling prices have fallen by 5% may also worry investors, as it could potentially limit the company's future revenue and profit growth. Thus, in spite of the raised guidance for 2023, these factors might lead to a slightly negative performance in the short term for AMGN. However, longer term trends like the rising demand for their products could potentially counteract these short-term concerns and facilitate growth over time."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-04-23 to 2023-04-30, AMGN's stock price decreased from 237.77 to 233.75. Company news during this period are listed below:

[Headline]: AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
[Summary]: Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023.

[Headline]: Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript
[Summary]: Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q1 2023 Earnings Conference Call April 27, 2023 4:30 PM ETCompany ParticipantsArvind Sood - Vice President of Investor RelationsBob Bradway - Chairman and...

[Headline]: Amgen Inc. stock falls Friday, underperforms market
[Summary]: Shares of Amgen Inc. shed 0.25% to $239.74 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...

[Headline]: Piper Sandler Maintains AMGEN (AMGN) Overweight Recommendation
[Summary]: 

[Headline]: Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock
[Summary]: Many Amgen Inc. ( NASDAQ:AMGN ) insiders ditched their stock over the past year, which may be of interest to the...

From 2023-04-30 to 2023-05-07, AMGN's stock price decreased from 233.75 to 230.62. Company news during this period are listed below:

[Headline]: Why Amgen Stock Was Sickly Today
[Summary]: What happened Investors are often encouraged when one of their companies bulks up by acquiring a peer. But that sentiment can turn sour if the takeover target stumbles. This was the impetus behind Amgen's (NASDAQ: AMGN) nearly 3% decline on the stock market Wednesday.

[Headline]: Weight-Loss Drugs Will Be Blockbusters. Here’s the Stock to Buy.
[Summary]: Everyone is talking about Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic. Now, the drugs are poised to go from conversation starters to profit makers.

[Headline]: 7 Blue-Chip Stocks to Buy in May 2023
[Summary]: While large-capitalization enterprises don’t offer much excitement, current circumstances may call for the best blue-chip stocks to buy. Frankly, it’s getting a little bit toasty on Wall Street, which is why stability may come at a premium. Naturally, the failure of First Republic – the third such collapse of a banking enterprise this year – generated plenty of jitters. Despite JPMorgan Chase (NYSE:JPM) CEO Jamie Dimon’s encouraging words that the FRC takeover averted a crisis, circumstances sti

[Headline]: Amgen Inc. stock outperforms competitors on strong trading day
[Summary]: Shares of Amgen Inc. rose 2.00% to $236.53 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...

[Headline]: 2 Best Biotech Stocks to Buy Right Now
[Summary]: Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-05-07, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-05-07 to 2023-05-14) is down by 1-2%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. stocks have persistently outperformed competitors on the stock market even amidst slight declines.
2. The company continues to maintain a strong reputation in the Biotechnology sector, with several financial institutions maintaining positive ratings.
3. Despite fluctuations in the market, shares of AMGN have exhibited some resilience, gaining value on specific trading days.

[Potential Concerns]:
1. The stock has showcased a declining trend over the past weeks with stock prices going from 237.77 to 230.62. 
2. Issues were seen in insider trading where some insiders disposed of US$5.2m worth of stock, raising concerns.
3. The company's financial results for the first quarter of 2023 failed to generate an upward momentum for the stock.

[Prediction & Analysis]:
Based on the recent consecutive weeks of steadily declining stock prices and negative signals such as insider sell-offs, it is predicted that the company's stocks will further decrease in the upcoming week. The market often interprets the disposal of stocks by insiders as signs of little confidence in the company's performance. However, being a significant player in the Biotechnology sector, the company's stock might still outperform other stocks in the sector and manage to reduce the margin of decrease. Therefore, it's predicted that AMGN will experience a modest decline by 1-2% for the upcoming week (2023-05-07 to 2023-05-14)."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-05-07 to 2023-05-14, AMGN's stock price decreased from 230.62 to 227.13. Company news during this period are listed below:

[Headline]: DICE Therapeutics: Worth A Roll At The Right Price
[Summary]: DICE Therapeutics recently posted encouraging Phase 1c data from its lead candidate, psoriasis therapy DC-806. Check out my recommendation on DICE stock.

[Headline]: Amgen Inc. stock underperforms Monday when compared to competitors
[Summary]: Shares of Amgen Inc. slipped 0.81% to $234.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...

[Headline]: Amgen Inc. (NASDAQ:AMGN) Shares Could Be 42% Below Their Intrinsic Value Estimate
[Summary]: Key Insights Amgen's estimated fair value is US$405 based on 2 Stage Free Cash Flow to Equity Amgen's US$235 share...

[Headline]: May Dogs Of The Dow: Buy 2, Watch 4
[Summary]: The Dow adds a stock if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Click for our lists.

[Headline]: Novartis CEO criticizes US, EU efforts to curb drug company power
[Summary]: Novartis CEO pushes back against government attempts to direct pharma RD

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-05-14, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-05-14 to 2023-05-21) is down by 3-4%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. A key insight report has shown that Amgen's shares could potentially be 42% below their intrinsic value estimate, suggesting substantial room for price growth.
2. Amgen is included in the discussion of ""Dogs of the Dow"", indicating it is considered as a company with an excellent reputation, sustained growth, and interest from a large number of investors.

[Potential Concerns]:
1. Amgen's stock underperformed when compared to its competitors on a Monday trading session, indicating possible investor concerns or flagging market sentiment about the company.
2. Another report criticizes US and EU efforts to curb drug company power, which could lead to tighter regulations and lower profitability for Amgen.

[Prediction & Analysis]:

Based on these recent events, there are few positive catalysts that could drive the price up in the short term. Although there's an insight suggesting that the stock is undervalued, it seems like it hasn't enticed investors to push the price up recently. On the contrary, its underperformance against peers and potential regulatory tightening could dampen investor sentiment, leading to downward price movement.

While Amgen's inclusion in the notable ""Dogs of the Dow"" suggests a strong long-term outlook, the company seems to face shorter-term pressures. Combined with a lack of other available positive catalysts to overcome these concerns, this could result in further price decrease in the coming week. Therefore, the stock price is predicted to be down by 3-4% for the week of 2023-05-14 to 2023-05-21. Nevertheless, the potential upside suggested by the intrinsic value estimate implies that this downward trend could just be a temporary downturn before a rebound.
"
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-05-14 to 2023-05-21, AMGN's stock price decreased from 227.13 to 219.90. Company news during this period are listed below:

[Headline]: Horizon Tumbles — Taking Seagen, Prometheus With It — As FTC Blocks Amgen Takeover
[Summary]: The FTC plans to block Amgen's takeover of Horizon. The move reverberated across biotechs, with an HZNP stock crash leading the way.

[Headline]: Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears
[Summary]: Investors are scrambling to assess the fallout of a U.S. regulatory challenge against Amgen Inc's proposed $27.8 billion acquisition of Horizon Therapeutics Plc, with some fearing a spillover to other big deals in the drug sector.  While investors are accustomed to regulators under U.S. President Joe Biden citing potential harm to consumers in objecting to many large mergers, the U.S. Federal Trade Commission's (FTC) lawsuit filed on Tuesday surprised those who had brushed off the antitrust risk in Amgen's deal because of its limited business overlap with Horizon.

[Headline]: Amgen/FTC: deal bar ignores realities of pharma food chain
[Summary]: No deal is fully inoculated against regulatory intervention.  In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate.  On Tuesday, the US Federal Trade Commission sued to block the deal.

[Headline]: Unusual Put Option Trade in AMGEN (AMGN)  Worth $9,481.50K
[Summary]: 

[Headline]: U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents
[Summary]: The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-05-21, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-05-21 to 2023-05-28) is down by 2-3%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen's aggressive expansion and growth strategy: The attempted acquisition of Horizon Therapeutics showcases Amgen's intent to grow and broaden its portfolio in the biotechnology sector. 

[Potential Concerns]:
1. Antitrust concerns: Amgen's proposed acquisition of Horizon Therapeutics has been met with regulatory pushback as the U.S. Federal Trade Commission (FTC) has filed a lawsuit to block the deal, citing potential harm to consumers.
2. Legal setbacks: Amgen has failed to revive patents for its cholesterol-lowering drug, Repatha, in a Supreme Court lawsuit against French pharma company Sanofi SA, potentially affecting its revenue streams.
3. Speculation of stock fall: The unusual put option trade for Amgen, worth over $9 million dollars, suggests that some investors anticipate a drop in Amgen's stock price in the near future.

[Prediction & Analysis]:

Against the backdrop of these developments, the forecast for Amgen's stock price in the upcoming week tends towards a likely decrease. The FTC's inhibition of the Horizon takeover deal represents a prohibitive factor and could likely foster investor anxiety about the potential for further regulatory issues in the future. This, compounded by the verdict against the company's patent reinstatement efforts, has succeeded in creating an atmosphere of uncertainty surrounding the company's future prospects. The substantial put option trade also signals a lack of investor confidence in the stock's short-term performance. 

Although one may argue that the company’s aggressive expansion attempts show an ambitious growth strategy which might foster confidence, the current concerns significantly overshadow these. Based on these factors, it can be inferred that the stock price of Amgen Inc. may trend downwards by roughly 2-3% over the course of the next week."
"[Company Introduction]:

Amgen Inc is a leading entity in the Biotechnology sector. Incorporated and publicly traded since 1983-06-17, the company has established its reputation as one of the key players in the market. As of today, Amgen Inc has a market capitalization of 142678.45 in USD, with 535.18 shares outstanding.

Amgen Inc operates primarily in the US, trading under the ticker AMGN on the NASDAQ NMS - GLOBAL MARKET. As a dominant force in the Biotechnology space, the company continues to innovate and drive progress within the industry.

From 2023-05-14 to 2023-05-21, AMGN's stock price decreased from 227.13 to 219.90. Company news during this period are listed below:

[Headline]: Wall St falls as Home Depot, retail sales data weigh
[Summary]: U.S. stocks fell on Tuesday after a dour forecast from Home Depot and April retail sales data pointed to consumers feeling the pinch from rising prices and interest rates, ahead of crucial debt limit talks.

[Headline]: Factbox-Amgen-Horizon deal joins mega mergers facing regulatory heat
[Summary]: A U.S. antitrust regulator said on Tuesday it will sue to stop Amgen's $27.8 billion deal for Horizon Therapeutics Plc, as it would give Amgen ""monopoly positions"" in treatments for thyroid eye disease and chronic refractory gout.

[Headline]: UPDATE 5-US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics
[Summary]: The U.S. Federal Trade Commission said on Tuesday it has filed a lawsuit to stop Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics Plc in a rare move to block a large pharmaceutical deal.  The FTC said it opposed the deal because of concern that Amgen would leverage its big selling drugs to pressure insurance companies and pharmacy benefit managers to give favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.  The FTC decision to stop this acquisition marks a change.

[Headline]: CORRECTED-US STOCKS-Wall Street closes lower after Home Depot outlook, US retail sales
[Summary]: U.S. stock indexes closed lower on Tuesday after a disappointing forecast from Home Depot and U.S. retail sales data for April pointed to softer consumer spending, while uncertainty about interest rates and debt limit negotiations weighed on sentiment.  Home Depot declined 2.15% as one of the biggest drag on both the Dow Industrials and S&P 500 after the home improvement retailer cut its annual sales forecast and projected a steeper-than-expected decline in profit.

[Headline]: Amgen Inc. stock falls Wednesday, underperforms market
[Summary]: Shares of Amgen Inc. sank 0.32% to $225.02 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

From 2023-05-21 to 2023-05-28, AMGN's stock price decreased from 219.90 to 213.51. Company news during this period are listed below:

[Headline]: SGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were Culled
[Summary]: 

[Headline]: 14 Best Healthcare Dividend Stocks to Buy
[Summary]: In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]

[Headline]: Amgen Inc. stock underperforms Wednesday when compared to competitors
[Summary]: Shares of Amgen Inc. slid 1.39% to $221.32 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

[Headline]: A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
[Summary]: When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids.  In fact, J&J is in the process of spinning off that business into an entity called Kenvue.  What is J&J's top revenue driver?

[Headline]: Is the Options Market Predicting a Spike in Amgen (AMGN) Stock?
[Summary]: Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.

[Basic Financials]:

No basic financial reported.

Based on all the information before 2023-05-28, let's first analyze the positive developments and potential concerns for AMGN. Come up with 2-4 most important factors respectively and keep them concise. Most factors should be inferred from company related news. Then let's assume your prediction for next week (2023-05-28 to 2023-06-04) is up by 0-1%. Provide a summary analysis to support your prediction. The prediction result need to be inferred from your analysis at the end, and thus not appearing as a foundational factor of your analysis.","[Positive Developments]:
1. Amgen Inc. continues to be recognized as a key player in the biotechnology sector which reflects investor's confidence.
2. The enduring interest in Amgen stocks in the options market predicts a potential spike in its share value.

[Potential Concerns]:
1. The U.S. Federal Trade Commission sued to block Amgen's $27.8 billion deal for Horizon Therapeutics. This uncertainty can negatively impact investor sentiment.
2. Additionally, Amgen's share price has been on a steady decline over the last two weeks, dropping from 227.13 to 213.51.

[Prediction & Analysis]:

Despite recent drawbacks, Amgen has long been a cornerstone in the biotechnology sector with a solid history of performance. The options market has shown sustained interest in Amgen stocks, indicating potential growth. Concerns over the possible regulatory blockage of the proposed mega-merger might have temporarily dented investor sentiment, leading to the steady decline seen in the past weeks.

This dip, however, might possibly inspire opportunistic buys in the next week as investors might see it as a good entry point, given the intrinsic value of the company and potential future growth from its operations and research. On top of that, the healthcare sector was not severely affected by the overall dip in the stock market, suggesting Amgen's resilience.

Taking all these factors into account, it is reasonable to predict a modest increase by up to 1% in Amgen's stock price for the next week (2023-05-28 to 2023-06-04). This prediction is also in line with the typical fluctuation range of biotechnology stocks and reflects a conservative outlook amid prevailing market uncertainties."
